Bayer's Monsanto has sued Pfizer, BioNTech and Moderna, for allegedly misusing its messenger RNA technology in COVID vaccines ...

The problem with drug patents is that they end, leading to patent cliffs. That's when cheaper generic versions of a drug take ...

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer Inc. (NYSE:PFE) is included among the 13 Best January Dividend Stocks to Invest in. Pfizer Inc. (NYSE:PFE) is among ...

The end of a short-lived, COVID-related revenue surge has brought Pfizer's stock lower. But sellers have ignored all the ...

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...

Jim Cramer has a reputation for getting market calls wrong, but what if you put $1,000 in Inverse Cramer at the start of 2025 ...

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically ...

How $2,670 split across three durable high-yield stocks can generate $300 in annual dividends without risky payouts.